West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.

TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.

TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.

OPXS' Q1 earnings per share fall sharply year over year despite double-digit revenue growth, as higher gold costs, legacy contract pressures and...

OPXS' Q1 earnings per share fall sharply year over year despite double-digit revenue growth, as higher gold costs, legacy contract pressures and...

HUM heads into Q4 with declining medical membership and rising costs, clouding earnings despite expectations for solid revenue growth.

BUD heads into Q4 earnings with expectations for revenue and EPS growth, but volume pressures, costs and macro headwinds could test investor optimism.

FIS heads into Q4 earnings with banking and capital markets growth set to boost revenue and EBITDA, though rising costs could partly offset positives.

FIS heads into Q4 earnings with banking and capital markets growth set to boost revenue and EBITDA, though rising costs could partly offset positives.

RDN beats Q4 estimates as MI's new insurance jumps 20%, lifting premiums and book value despite higher expenses.